Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297 別名：Mereletinib

Osimertinib (AZD9291)化学構造

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ 価格(税別)  
JPY 12000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

文献中Selleckの製品使用例(289)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明 Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
特性 Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
ターゲット
L858R/T790M EGFR [1]
(LoVo cells)		 Exon 19 deletion EGFR [1]
(LoVo cells)		 WT EGFR [1]
(LoVo cells)
11.44 nM 12.92 nM 493.8 nM
体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-9/BRc1 NUfudFhRTnWwY4Tpc44hSXO|YYm= NX7hT4VXPTBibl2= NGTESWczPCCq NUPtXHdPTE2VTx?= MYnpcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= M1XleFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N|I2Lz5{NUS3O|MzPTxxYU6=
PC-9/ERc1 M3HuTGZ2dmO2aX;uJGF{e2G7 M{L2d|UxKG6P MVSyOEBp M4DCSWROW09? MV7pcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= Ml7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
VP-2 MnXHSpVv[3Srb36gRZN{[Xl? NEH3NY42OCCwTR?= NF\GcW4zPCCq MU\EUXNQ NGPucmNqdmS3Y3XzJIV5eHKnc4Ppc44hd2ZidHjlJJBzd2Gyb4D0c5Rq[yCEQ1ytNkBn[W2rbImgcYVu[mW{IFLJUS=> MljyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
PC-9/BRc1 M4n3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P2[lUxKG6P M1:1R|ExKGR? MkfDSG1UVw>? M4DzNYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?= MkSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
PC-9/ERc1 M1f1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP1fnQ2OCCwTR?= NHvaS|UyOCCm NEDP[JNFVVOR M1rOO4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?= NYDCfXI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LYUFUxKG6P M3fPPVExKGR? NV\NUXFETE2VTx?= M3nZSolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?= MnvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
PC9 GR4 NIHUbnVHfW6ldHnvckBCe3OjeR?= MlnkNE0yOCEQvF2= NFG5THg4OiCq MnztbY5pcWKrdIRCpGVITlJicHjvd5Bpd3K7bHH0bY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[:Kh M1vROlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 NYDxNopSTnWwY4Tpc44hSXO|YYm= M3vlZVAuOTBizszN MUK3NkBp NFHlclJqdmirYnn0d{BYXCCHR1\SJIF1KGyxdzDjc45k\W62cnH0bY9vew>? M2eyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 GR4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBWmUxNTFyIN88US=> MmHhO|IhcA>? NWThcpVjcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4S0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
BAF3 NHrkdY1HfW6ldHnvckBie3OjeR?= M3W1c|czKGh? NFiwdYlIUTVyIE2gNE4xODB|IN88US=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 NH;T[JBHfW6ldHnvckBie3OjeR?= M4XSbVczKGh? NYT6elNFT0l3MDC9JFAvODByMzFOwG0> M2nJPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3 MnzYSpVv[3Srb36gZZN{[Xl? NWCwUnk3PzJiaB?= MV\HTVUxKD1iMD6wNFEh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 NV\xcVhoTnWwY4Tpc44h[XO|YYm= NU\s[FZjPzJiaB?= MoThS2k2OCB;IECuNFAyKM7:TR?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9 MoPZSpVv[3Srb36gZZN{[Xl? M3TFRlczKGh? M{PqXmdKPTBiPTCwMlAxOiEQvF2= NIXBTG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3 NHv5NJdHfW6ldHnvckBie3OjeR?= M3zoZ|QhcA>? M2HTfmVEPTBiPTCwMlAxOiEQvF2= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 M{jhSmZ2dmO2aX;uJIF{e2G7 NITubpc{KGh? M3P1PWlEPTBiPTCwMlAxOjVizszN MoLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
H1975 MUnGeY5kfGmxbjDhd5NigQ>? NXjqVY5bOyCq NHTmO4VKSzVyIE2gNE4xODJ3IN88US=> NX:yOYRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N|M5OjlpPkK3OFM{QDJ7PD;hQi=>
H3255 MWPGeY5kfGmxbjDhd5NigQ>? MXizJIg> NW\vZ3c6UUN3MDC9JFAvODB2MTFOwG0> NYHaWHN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N|M5OjlpPkK3OFM{QDJ7PD;hQi=>
NCI-H1975 MkXlSpVv[3Srb36gZZN{[Xl? MUC3NkBp MnvIS2k2OCB;IECuNFA2KM7:TR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9 NUXRRmRkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M1PYS|czKGh? NHjweXFKSzVyIE2gNE4xODZ3IN88US=> MoHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
NCI-H1975 MojsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MYK3NkBp M373XGlEPTBiPTCwMlAyODVizszN MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
Sf21 MXnGeY5kfGmxbjDhd5NigQ>? NU\uZmRjUUN3MDC9JFAvODF{IN88US=> NV\4O4tzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVYzPjdpPkK3PVk3OjZ5PD;hQi=>
PC9-DRH MVrGeY5kfGmxbjDhd5NigQ>? Mo\4NkBp MmHUTWM2OCB;IECuNFE{KM7:TR?= NHTlbok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3 M4DlNmZ2dmO2aX;uJIF{e2G7 NUTNTY5JPzJiaB?= MkPDS2k2OCB;IECuNFE{KM7:TR?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 NEC0cWxHfW6ldHnvckBie3OjeR?= NGPwNnE6PiCq NEfKUYdGSzVyIE2gNE4xOTRizszN MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
HCC827 NHrNV5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M4S1TVk3KGh? NVrx[ZBjTUN3MDC9JFAvODF2IN88US=> NHfvfYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975 NVrHbmZpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M{nnRVk3KGh? Mke5SWM2OCB;IECuNFE1KM7:TR?= M3PFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
NCI-H1975 M4PMZ2Z2dmO2aX;uJIF{e2G7 Mm\LNkBp M3jGTGlEPTBiPTCwMlAyPSEQvF2= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
H1975 MYLGeY5kfGmxbjDhd5NigQ>? M2fLVVIhcA>? NViwZmRFUUN3MDC9JFAvODF3IN88US=> Mof2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkiyOVMoRjJ4OU[4NlU{RC:jPh?=
PC9 NWnP[2hVTnWwY4Tpc44h[XO|YYm= NYD2d4ZKOiCq M13EdGlEPTBiPTCwMlAyPyEQvF2= Mlq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkiyOVMoRjJ4OU[4NlU{RC:jPh?=
NCI-H1975 MoLMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4DYZVczKGh? NVS0bHNWUUN3MDC9JFAvODF7IN88US=> MnfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
NCI-H1975 MmG1SpVv[3Srb36gZZN{[Xl? NGKxZVE6PiCq MXHFR|UxKD1iMD6wNVkh|ryP MlPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkWyOlkoRjJ6MkK1NlY6RC:jPh?=
NCI-H1975 NIPRXlNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1e2R|k3KGh? MnflSWM2OCB;IECuNFE6KM7:TR?= NVz0NIZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NFM6QTFpPkK4OlA{QTlzPD;hQi=>
NCI-H1975 NIS2NWhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M3T6PFczKGh? NGrPbndKSzVyIE2gNE4xOTlizszN NIj2ZoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N|M1OCd-Mkm4OVM{PDB:L3G+
HCC827 NXPP[ZZiTnWwY4Tpc44h[XO|YYm= NUDRTY56OiCq MV7JR|UxKD1iMD6wNlMh|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
NCI-H1975 NIDGfXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NFu1[2U4OiCq MkX2TWM2OCB;IECuNFI{KM7:TR?= NFj4dIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N|Q6OjZ:L3G+
PC9 NUTNNIFvS3m2b4TvfIlkcXS7IHHzd4F6 MVW3NkBp MYHHTVUxKD1iMD6wNlMh|ryP MorNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975 Mor5R5l1d3SxeHnjbZR6KGG|c3H5 Mor5O|IhcA>? MlPNS2k2OCB;IECuNFI1KM7:TR?= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
HCC827 Moj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NIPwdXg4OiCq NX3ZXJBIUUN3MDC9JFAvODJ3NDFOwG0> Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO|IoRjJ7NUe2NlczRC:jPh?=
HCC827 NH3hN45CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NVjRZ4xZPzJiaB?= M1TjR2lEPTBiPTCwMlAzPyEQvF2= NEfkSpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
HCC827 NHHWZo9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M3;pd|czKGh? NVLCfo9yUUN3MDC9JFAvODJ5IN88US=> MmTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
NCI-H1975 NHXCV3VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M4HGeFczKGh? M3KxSGlEPTBiPTCwMlA{KM7:TR?= NHLSWIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzN|U4QSd-MkiwN|M2Pzl:L3G+
H3255 MnjMSpVv[3Srb36gZZN{[Xl? M3TzOVczKGh? MWXHTVUxKD1iMD6wN|Mh|ryP M1zq[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255 M3\odWZ2dmO2aX;uJIF{e2G7 M4XHdFIhcA>? M4DCVGlEPTBiPTCwMlA{PiEQvF2= M4TBUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975 NIHwd25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MUO3NkBp NH20bodKSzVyIE2gNE4xPDFizszN NX7XbYFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|AyQTJpPkK5O|MxOTl{PD;hQi=>
NCI-H1975 NHHDepVHfW6ldHnvckBie3OjeR?= M333OlEhcA>? NH:5UGdKSzVyIE2gNE4xPDFizszN NXLNNGF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
BAF3 MmK4SpVv[3Srb36gZZN{[Xl? NWHrNnpzPCCq MWnFR|UxKD1iMD6wOFMh|ryP MljOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 M3TtcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NVPCd|V1PzJiaB?= MUHJR|UxKD1iMD6wOFczKM7:TR?= M1fE[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
NCI-H1975 M{H0e2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M2\rSlczKGh? MX;JR|UxKD1iMD6wOVIh|ryP NV[ydmpyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9 NF;0b5pHfW6ldHnvckBie3OjeR?= NX7iOVV6OiCq NIPSNZhKSzVyIE2gNE4xPTZizszN NIjaXVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975 NGPqOJdEgXSxdH;4bYNqfHliYYPzZZk> MljnO|IhcA>? M3fEc2lEPTBiPTCwMlA3KM7:TR?= M4H6[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
HCC827 M{\3UGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MULJR|UxKD1iMD6wOlE3KM7:TR?= MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
NCI-H1975 MoDhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? Mnm3TWM2OCB;IECuNFY4KM7:TR?= MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HaCaT NFHmbJZHfW6ldHnvckBie3OjeR?= M1v0OFMhcA>? NHPnNWhKSzVyIE2gNE4xPzN5IN88US=> M33vOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN|gzQTxxYU6=
NCI-H1975 MnnhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M2LsVVczKGh? M3fSW2lEPTBiPTCwMlE{KM7:TR?= NIXXe4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
A431 NGS1b3lHfW6ldHnvckBie3OjeR?= MV[xJIg> NGHmd|JKSzVyIE2gNE4yPDFizszN M1fZS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVI3Lz5{OUWzOFkzPjxxYU6=
A549 NFn6NIhHfW6ldHnvckBie3OjeR?= NX\xS|NwUUN3MDC9JFAvOTVizszN NIL6XGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
Calu3 M{jLcGN6fG:2b4jpZ4l1gSCjc4PhfS=> NEjZbXQ4OiCq M4\neGdKPTBiPTCwMlI3PCEQvF2= NXrze5RSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
Sf9 MVjGeY5kfGmxbjDhd5NigQ>? M2rKdVIxKG2rboO= M3fQdGlEPTBiPTCwMlI4QCEQvF2= M1q0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEiyNVUyLz5{OES4NlE2OTxxYU6=
BAF3 MYDGeY5kfGmxbjDhd5NigQ>? NUfCbXBqPzJiaB?= NIH1RoFIUTVyIE2gNE4{KM7:TR?= NW\kSJN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 M1zNcmZ2dmO2aX;uJIF{e2G7 MVS3NkBp NX\3elBTT0l3MDC9JFAvOzFizszN NY\XNFV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H460 NXXOe3dpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MlXnO|IhcA>? MlfaTWM2OCB;IECuOFE2QSEQvF2= MorKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
LoVo NHj6e3RHfW6ldHnvckBie3OjeR?= MV:yJIg> MX;JR|UxKD1iMD60PEDPxE1? NVPMOo1CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV|PD;hQi=>
LoVo MWLGeY5kfGmxbjDhd5NigQ>? NI\pd2IzKGh? NGXlOFhKSzVyIE2gNE41QCEQvF2= MofRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OU[yOlcoRjJ5OUm2NlY4RC:jPh?=
A549 NV\rPXlwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NYTr[FFqPzJiaB?= M1\V[mlEPTBiPTCwMlQ5PiEQvF2= M1:1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3 NWfvS4I5TnWwY4Tpc44h[XO|YYm= NUPHXmhIPzJiaB?= MkDSS2k2OCB;IECuOUDPxE1? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A549 NULuWHlESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NVHlXoxKPzJiaB?= MorFTWM2OCB;IECuOVMh|ryP NH7Edoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549 MV3DfZRwfG:6aXPpeJkh[XO|YYm= MnjWO|IhcA>? M4i3W2lEPTBiPTCwMlU{KM7:TR?= M{\FNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN|QxLz5{OUi1N|M1ODxxYU6=
BAF3 NYrGb3g3TnWwY4Tpc44h[XO|YYm= NY\5WI82PzJiaB?= MoXSS2k2OCB;IECuOVUh|ryP MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 MVzGeY5kfGmxbjDhd5NigQ>? MnPBO|IhcA>? M3:0XGdKPTBiPTCwMlU3KM7:TR?= NYXPRottRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HEK293 MknDSpVv[3Srb36gZZN{[Xl? NFHQW2RKSzVyIE2gNE42PyEQvF2= M3nnU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3 NFn2[3dHfW6ldHnvckBie3OjeR?= MnH2O|IhcA>? M3HKOWdKPTBiPTCwMlU6KM7:TR?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A431 NGHk[nFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NHrHN3VKSzVyIE2gNE43OTV4IN88US=> NFG2SVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
HT-29 M3;PWmN6fG:2b4jpZ4l1gSCjc4PhfS=> Mmf0O|IhcA>? NXrp[4huUUN3MDC9JFAvPjVizszN NHfVfG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
A431 NHrPSWNHfW6ldHnvckBie3OjeR?= NHj1NpU6PiCq M3z0O2VEPTBiPTCwMlY3PyEQvF2= M{O5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
A431 M3KyUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NYfVbld7QTZiaB?= NITNdJFGSzVyIE2gNE43PyEQvF2= MkLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
A431 M2jB[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M3rtWFczKGh? M4HxbmlEPTBiPTCwMlY5PSEQvF2= MmnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
A431 M4nRbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NEjkfVI6PiCq MWXFR|UxKD1iMD63JO69VQ>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZyM{m5NUc,Ojh4MEO5PVE9N2F-
A549 NVnHWYdMS3m2b4TvfIlkcXS7IHHzd4F6 MoLyO|IhcA>? MmXrTWM2OCB;IECuPFch|ryP NXXkflF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV|PD;hQi=>
A431 M3LBdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MXy3NkBp M3W0S2lEPTBiPTCwMlg6OyEQvF2= NFHIbHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN|E3Ozl:L3G+
BA/F3 NUXpelJCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Mmn0O|IhcA>? NFHjUZBKSzVyIE2gNUDPxE1? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
BAF3 NH;US4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3v5eFczKGh? NF\IXGNIUTVyIE2gNU4zKM7:TR?= M1PNOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H2122 MUTGeY5kfGmxbjDhd5NigQ>? NXrob3lmPzJiaB?= MkDNS2k2OCB;IEGuNkDPxE1? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A431 NILFe|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NY\TUGZrPzJiaB?= NWH6RpZ5UUN3MDC9JFEvOjRizszN MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431 NYTMeZFSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NH[5VWI4OiCq M2e3emlEPTBiPTCxMlI3KM7:TR?= M{n5b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
A431 NF\KRYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NETX[5g4OiCq MYDJR|UxKD1iMT62NFQh|ryP MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB|M{W3PUc,OjhyM{O1O|k9N2F-
A549 MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MUm5OkBp M2PGb2VEPTBiPTCxMlg{KM7:TR?= M1f0R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
CHL NGXsOmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{fIdlczKGh? MljYS2k2OCB;IEKuPUDPxE1? Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1355 M2TmSWZ2dmO2aX;uJIF{e2G7 MljuO|IhcA>? NY\hTmJST0l3MDC9JFMh|ryP MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1703 MoPuSpVv[3Srb36gZZN{[Xl? MUe3NkBp M3rsZ2dKPTBiPTCzMlUh|ryP NUHKWnZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549 M4fNTWZ2dmO2aX;uJIF{e2G7 NIHBZlA4OiCq NU\NNJpQT0l3MDC9JFMvPSEQvF2= M{\SdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
CHO M4fXXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYK3NkBp M2KxVGdKPTBiPTC0MlIh|ryP MkHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3 NHLhOWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MkPPO|IhcA>? MmXmTWM2OCB;IESuOlEh|ryP M{X4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
BAF3 M1vVS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M{D3XFczKGh? M2LLc2lEPTBiPTC1MlE2KM7:TR?= NXjz[Yw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BEAS2B MlHJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? Mlv4O|IhcA>? MUjJR|UxKD1iMUSuPUDPxE1? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975 MXfGeY5kfGmxbjDhd5NigQ>? MkK0NkBp NYfie2UzUUN3MDC9JFE2KM7:TR?= M3PoW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
PC9 NWfCSIF2TnWwY4Tpc44h[XO|YYm= NUHlTVFnOiCq M3fscGlEPTBiPTCxO{DPxE1? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
LoVo NVu4WGU6TnWwY4Tpc44h[XO|YYm= MnjZNkBp M4jXO2lEPTBiPTC0PFAh|ryP NHfzOYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
NCI-H1975 MVHBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl? NFr2UnZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDJwNTDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=> M4G2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
rat hepatocytes MofmSpVv[3Srb36gZZN{[Xl? MlTXTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK|Yh[2WubIO= MkHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
human hepatocytes MlnmSpVv[3Srb36gZZN{[Xl? NX2xcJlYUW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDt[YF{fXKnZDDw[ZIhOTBpNjDj[Yxtew>? NVnme21iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
NCI-H1975 NHTOc3lCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= MUTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x? M{e5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975 NGjvclVHfW6ldHnvckBie3OjeR?= NYfvTY14W2WuZXP0bZZqfHliaX7k[ZgtKHKjdHnvJI9nKEmFNUCg[o9zKEWJRmKgWFc6OE1xTEi1PHIh\G:3YnzlJI12fGGwdDDlfJBz\XO|aX7nJIh2dWGwIF7DTU1JOTl5NTDj[YxteyC2bzDJR|UxKG[xcjD3bYxlKHS7cHWgSWdHWiCneIDy[ZN{cW6pIHj1cYFvKEF2M{GgZ4VtdHN? MlvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{CxPVIoRjJ7N{OwNVkzRC:jPh?=
NCI-H1975 MUPBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl? NHrkbZRCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBGT0[UIGS3PVBON0x6NUjSJIRwfWKuZTDteZRidnRiZYjwdoV{e2mwZzDoeY1idiCQQ1mtTFE6PzViY3XscJMhgGWwb3fyZYZ1\WRiaX6gRmFNSi:lIHH0bJlucWNiboXk[UBud3W|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEAyOCCvZz;r[{wheG9iYnnkJIZweiB{MTDkZZl{ M3rXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827 NYrCUI17SXCxcITvd4l{KGG|c3H5 Mon1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0Ok1CPzVyIHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDlZZJtgSCjcH;weI91cWNiY3XscJMh[XRiMzD1UUBi\nSncjCyOEBpenNiYomgRY5v\XirbjDWMWZKXENxcILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eTCoVpZjKD1iMT6zOEUq Ml\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
HCC827 NWHHZ4V[SXCxcITvd4l{KGG|c3H5 MUfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCHN{S2MWE4PTBiZHXs[ZRqd25ibYX0ZY51KGG|c3Xzd4VlKGG|IHzheIUh[XCxcITveIlkKGOnbHzzJIF1KDNidV2gZYZ1\XJiMkSgbJJ{KGK7IFHucoV5cW5iVj3GTXREN3C{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enliKGL2ZkA:KDJ5LkG0KUk> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
A549 NGTEZ4lHfW6ldHnvckBie3OjeR?= M3fhOHNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJGE2PDliY3XscJMh\XiycnXzd4lv\yC5aXzkMZR6eGViRVfGVk9MNVKjczDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6Uj;UO|kxVSCmb4XicIUhdXW2YX70 NF7OWI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
HCC827 NXjMeJdGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NYjtZpV5PzJiaB?= MoPsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ1O4Nlch[2WubIOgZZQhOSC3TTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y= M2TLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3 M3vuWWZ2dmO2aX;uJIF{e2G7 NFTTSmEzKGh? NFPPOm9KdmirYnn0bY9vKG:oIFXHSnIhXDd7MF2vUFg2QFJxQ{e5O3MhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVITi2rbnT1Z4VlKHKnY3XweI9zKHCqb4PwbI9zgWyjdHnvckBifCBzIITvJFMhfU1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCHR1[gd5RqdXWuYYTpc44h\m:{IEG1JI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M1n4eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
BAF3 MnzUSpVv[3Srb36gZZN{[Xl? NV\Mems1OiCq MWfJcohq[mm2aX;uJI9nKEWJRmKgNVlFN1R5OUDNM2M4QTeVIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHR1[tbY5lfWOnZDDy[YNmeHSxcjDwbI9{eGixconsZZRqd25iYYSgNUB1dyB|IIXNJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyPSCvaX7zJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NVzLW|lNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
NCI-H1975 NEXhUGdCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= M325VGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyC6ZX7v[5Ji\nSnZDDpckBUXE:FSz3Gc5hvOW63L17qeUBvfWSnIH3veZNmKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWvb4Kg[5Jwf3SqIHH0JFIxKG2pL3vnM4RigSxicH:gdYQh\m:{IEG0JIRigXNicnXsZZRqfmVidH:geY51emWjdHXkJINwdnS{b3y= MkXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|OUWyNVkoRjJ6M{m1NlE6RC:jPh?=
Caco2 M1S5bmZ2dmO2aX;uJIF{e2G7 MXGyJIg> MmXmSYZndHW6IILheIlwKG:oIHHwdIFz\W62IIDldo1m[WKrbHn0fUBnem:vIHLhd49t[XSncnHsJJNq\GVidH:gZZBq[2GuIIPp[IUhd3[ncjDhdIlk[Wxic3nk[UB1dyCkYYPvcIF1\XKjbDDzbYRmKG:4ZYKgbY4hcHWvYX6gR4FkdzJiY3XscJMh[XRiNTD1UUBqdmO3YnH0[YQh\m:{IEKgbJJ{ MmT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
A431 Mnr2SpVv[3Srb36gZZN{[Xl? MXXT[Yxm[3Srdnn0fUBz[XSrbzDv[kBGSzVyIH\vdkBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKgeI8hTUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy|IHjhdoJwemmwZzDFS2ZTNUx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ> MkTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
Caco2 MYfGeY5kfGmxbjDhd5NigQ>? MnL3NkBp MV;BdJBiemWwdDDw[ZJu\WGkaXzpeJkh[WO{b4PzJIFxcWOjbDD0c{Bj[XOxbHH0[ZJidCC|aXTlJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
Caco2 MUTGeY5kfGmxbjDhd5NigQ>? MoXUNkBp M{HRNmFxeGG{ZX70JJBmem2nYXLpcIl1gSCjY4Lvd5Mh[mG|b3zheIVz[WxidH:gZZBq[2GuIIPp[IUhcW5iaIXtZY4hS2Glb{KgZ4VtdHNiYYSgOUB2VSCrbnP1ZoF1\WRiZn;yJFIhcHK| NVixUGNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
NCI-H1975 NEWweXlHfW6ldHnvckBie3OjeR?= M2fpR|QhcA>? NGfGUnpKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRYt1KHCqb4PwbI9zgWyjdHnvckBifCCWaIKzNFgwW2W{NEezJJNqfGViYYSgNUB2VSCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NV;ETpp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827 MojoSpVv[3Srb36gZZN{[Xl? MmTMOEBp MVvJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NUO1c3R7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975 MnHPRZBweHSxc3nzJIF{e2G7 M3i0dlQ5KGh? MonjTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIF{e2W|c3XkJIF{KGOjc4Dhd4U{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK|IHL5JIludXWwb3Lsc5R1cW6p MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 NVHJUXVHSXCxcITvd4l{KGG|c3H5 NInEe2c1QCCq NFruToRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDlfI9vKDF7IHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDjZZNx[XOnLUOgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc> Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9 NYSyTpdFSXCxcITvd4l{KGG|c3H5 MVO0PEBp NWjOb45GUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDQR|kh[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO|ZYPz[YQh[XNiY3HzdIF{\S1|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n NHLNOGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
H3255 NVnybI1HSXCxcITvd4l{KGG|c3H5 MYO0PEBp MY\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh|MkW1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{Bk[XOyYYPlMVMh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd? NHXxcoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975 MYHBdI9xfG:|aYOgZZN{[Xl? M1LoV|Q5KGh? NX7NfoVwUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGG|c3Xzd4VlKGG|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd? M3vIbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9 MVjBdI9xfG:|aYOgZZN{[Xl? NH23SFY1QCCq MoDMTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 NH;0flFCeG:ydH;zbZMh[XO|YYm= MVe0PEBp MVvJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o NFWzcY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
H3255 NH71[nlCeG:ydH;zbZMh[XO|YYm= MnjsOFghcA>? NHm2foxKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o M2LZSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 NEjJTGlHfW6ldHnvckBie3OjeR?= M1vBfXNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KHSxIFnDOVAh\m:{IHj1cYFvKEF2M{GgZ4VtdHNiaHHyZo9zcW6pIIfpcIQufHmyZTDFS2ZT NIrzZ2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
human hepatocytes MVLGeY5kfGmxbjDhd5NigQ>? M4Lh[WlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5iaIXtZY4hcGWyYYTvZ5l1\XNiYYPz[ZN{\WRicHXyJI1qdGyrb36gZ4VtdHN? M{fXOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
rat hepatocytes NVPSbpEzTnWwY4Tpc44h[XO|YYm= M{iyUWlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{ NEP0bm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
A549, NCI-H1975 M1TjZ2Z2dmO2aX;uJIF{e2G7 MVHT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBGT0Zvc4TpcZVt[XSnZDD3bYxlKHS7cHWgSWdHWiCrbjDoeY1idiCDNUS5JINmdGy|IITvJGlEPTBiZn;yJGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJM> NETPZ289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
A549, PC9 MmTkSpVv[3Srb36gZZN{[Xl? Mk\yV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIHTlcIV1cW:wIH31eIFvfCCrbjDoeY1idiCSQ{mgZ4VtdHN? NXvTNVYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
HCC827 NIDQXXNCeG:ydH;zbZMh[XO|YYm= MkDETY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0OkB1dyCDN{WwJIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bm[XKueTDhdI9xfG:2aXOgZ4VtdHNiYYSgN{B2VSCjZoTldkAzPCCqcoOgZpkhSW6wZYjpckBXNU[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTyfUApWn[kIE2gNU4{PCC2bzCxMlY4LSl? Mon2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
NCI-H1975 NYq1bIh2TnWwY4Tpc44h[XO|YYm= NH7tNHBKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG2IEGgeI8hOTByIH7NJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTlyNkGxOEc,Ojl7ME[xNVQ9N2F-
A431 Mmj2SpVv[3Srb36gZZN{[Xl? MnLQV4Vt\WO2aY\peJkhemG2aX:sJJJifGmxIFnDOVAh\m:{IHj1cYFvKEF2M{GgZ4VtdHNib4\ldoV5eHKnc4Ppcochf2muZD30fZBmKEWJRmKgeI8hUUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy|IHX4dJJme3OrbnegSWdHWiCWN{mwUU9NQDV6UjDteZRidnR? MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N|koRjJ5MUOxOlM6RC:jPh?=
PC9 NF7jXZVCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= MV\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
A431 NXTUNmFUSW62aYT1cY9zKGGldHn2bZR6KGG|c3H5 M17jRmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u NVnQeGlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-EGFR / p-AKT / p-ERK; 

PubMed: 28416483     


PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib.

ABCB1; 

PubMed: 27649127     


The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.

28416483 27649127
Growth inhibition assay
Cell viability; 

PubMed: 31043587     


Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. *P < 0.05, **P < 0.01, ***P < 0.005 by t-test.

31043587
Immunofluorescence
Ki67 / γH2AX / p16; 

PubMed: 29212784     


PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. **P ≤ 0.01, ***P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.

29212784
体内試験 AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]

お薦めの試験操作（参考用のみ）

動物試験：

[2]
- 合併
  • 動物モデル： Mice bearing PC9 and H1975 xenograft tumors
  • 投薬量： ~5 mg/kg
  • 投与方法： p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 99 mg/mL (198.15 mM) warming
Water Insoluble
Ethanol '43 mg/mL warmed '43
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
混合させたのち直ちに使用することを推奨します。 		7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 499.61
化学式

C28 H33 N7 O2
CAS No. 1421373-65-0
Storage powder
in solvent
別名 Mereletinib
Smiles CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
投与量 mg/kg 動物平均体重 g 投与体積（動物毎） ul 動物数 匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02841579 Completed Drug: Osimertinib Non-Small Cell Lung Cancer MedSIR|AstraZeneca August 2016 Phase 2
NCT02771314 Unknown status Drug: AZD9291 Non Small Cell Lung Cancer Hellenic Oncology Research Group August 2 2016 Phase 2
NCT02529995 Completed Drug: AZD9291 40 mg|Drug: AZD9291 80 mg Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive AstraZeneca August 24 2015 Phase 1
NCT02491944 Completed Drug: AZD9291|Drug: [14C]AZD9291 Oncology AstraZeneca July 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

  • 回答：

    Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

selleck catalog

EGFRシグナル伝達経路

相関EGFR製品

  • Erlotinib (OSI-774)

    Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

  • Lapatinib (GW-572016)

    Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

Tags: Osimertinib (AZD9291)を買う | Osimertinib (AZD9291) ic50 | Osimertinib (AZD9291)供給者 | Osimertinib (AZD9291)を購入する | Osimertinib (AZD9291)費用 | Osimertinib (AZD9291)生産者 | オーダーOsimertinib (AZD9291) | Osimertinib (AZD9291)化学構造 | Osimertinib (AZD9291)分子量 | Osimertinib (AZD9291)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID